Free Testosterone: Sex- and Cycle-Related Differences, Normal Ranges, and Optimal Levels

What Is Free Testosterone and Why Does It Matter?

Free testosterone is the small fraction of total testosterone not bound to sex hormone-binding globulin (SHBG) or albumin. Only this unbound portion crosses cell membranes freely, binds androgen receptors, and produces measurable biological effects. Total testosterone can appear normal while free testosterone is low, or vice versa, making it a distinct and often more clinically relevant measurement.

The Binding Protein Problem

Roughly 44 to 65% of circulating testosterone binds tightly to SHBG, and another 33 to 54% binds loosely to albumin. The remaining 1 to 3% in men (and 0.5 to 2% in women) circulates unbound 1. Because SHBG concentrations shift with obesity, thyroid disease, liver function, aging, and exogenous estrogen, total testosterone is a poor surrogate for androgen activity in many patients.

How Free Testosterone Is Measured

The Endocrine Society's 2010 guideline on testosterone measurement states that equilibrium dialysis followed by liquid chromatography-mass spectrometry (LC-MS/MS) is the reference method for free testosterone. The immunoassay-based "direct" free testosterone test is widely available but has known accuracy problems, particularly at the low concentrations seen in women and hypogonadal men 2. The Vermeulen calculated free testosterone formula, which uses total testosterone, SHBG, and albumin, performs well against equilibrium dialysis and is acceptable when direct dialysis is unavailable 3.

Normal Free Testosterone Ranges in Men

Adult men maintain free testosterone between approximately 5.0 and 21.0 pg/mL by equilibrium dialysis, but that range shifts substantially with age and time of day 4. The Massachusetts Male Aging Study (MMAS) documented a 1 to 2% annual decline in total testosterone after age 30, with free testosterone falling faster because SHBG rises with age 5.

Age-Stratified Reference Intervals (Men)

| Age group | Free testosterone (pg/mL, equilibrium dialysis) | |---|---| | 20 to 29 | 9.3 to 26.5 | | 30 to 39 | 8.7 to 25.1 | | 40 to 49 | 7.2 to 24.0 | | 50 to 59 | 6.8 to 21.5 | | 60 to 69 | 5.9 to 18.3 | | 70+ | 5.0 to 15.8 |

Values adapted from the Endocrine Society reference population data 4 and the Framingham Heart Study ancillary cohort 6.

Diurnal Variation in Men

Free testosterone peaks between 06:00 and 08:00 and may be 20 to 25% lower by late afternoon 7. The Endocrine Society recommends a morning draw (07:00 to 10:00) for diagnostic samples in men. On TRT, draw timing relative to the last dose matters more than clock time.

What "Optimal" Means for Men on TRT

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism targets a mid-normal range free testosterone during TRT, generally 9 to 18 pg/mL by equilibrium dialysis, without chasing supraphysiologic levels 8. The guideline states: "We suggest aiming for testosterone concentrations in the mid-normal range for healthy young men." Free testosterone should be checked 3 to 6 months after initiating therapy and then annually once stable 8.

Normal Free Testosterone Ranges in Women

Free testosterone concentrations in women run 5- to 10-fold lower than in men, and they shift across the menstrual cycle, across reproductive life stages, and with oral contraceptive use. Interpreting a single value without knowing cycle phase can lead to misclassification 9.

Follicular Phase

During the follicular phase (days 1 to 13), ovarian androgen output is relatively low. Free testosterone by equilibrium dialysis typically ranges from 0.3 to 2.5 pg/mL in reproductive-age women 10.

Mid-Cycle Surge

Around the LH surge (days 13 to 15), free testosterone rises 10 to 20% above follicular-phase values, reaching approximately 0.8 to 3.4 pg/mL 10. This surge likely contributes to libido enhancement near ovulation. The rise is driven by both increased ovarian androgen secretion and a transient dip in SHBG.

Luteal Phase

Free testosterone returns toward follicular-phase levels during the luteal phase (days 16 to 28). The adrenal contribution to circulating androgens remains relatively constant across all phases, while ovarian contribution peaks mid-cycle 11.

Age- and Life-Stage-Related Changes in Women

| Life stage | Free testosterone (pg/mL, approximate) | |---|---| | Reproductive (20 to 40) | 0.3 to 3.4 | | Perimenopause | 0.2 to 2.8 | | Postmenopause (no HRT) | 0.1 to 1.8 | | Postmenopause (on estrogen HRT) | often <0.5 due to SHBG rise |

Oral estrogen therapy raises SHBG substantially, which suppresses free testosterone even when total testosterone is unchanged. This is a key reason why some women on oral HRT report persistent low-libido symptoms despite normal total testosterone 12.

The SHBG Effect: Why Two Patients With the Same Total T Look Very Different

SHBG is the primary modulator of free testosterone availability, and its concentration is highly sensitive to metabolic and hormonal inputs. A working grasp of SHBG dynamics is necessary for accurate free testosterone interpretation.

Conditions That Raise SHBG (Lower Free T)

• Oral estrogens (including combined oral contraceptives)
• Hyperthyroidism
• Cirrhosis and other liver diseases causing increased production
• Anorexia and caloric restriction
• Aging (especially after 50 in men)

Women taking oral estrogen-containing contraceptives can see SHBG rise 3- to 4-fold, reducing free testosterone to near-undetectable levels even when total testosterone is within range. A 2010 study in the Journal of Sexual Medicine found that SHBG remained elevated for 6 months or more after stopping oral contraceptives in some women 13.

Conditions That Lower SHBG (Raise Free T)

• Obesity and insulin resistance
• Hypothyroidism
• Androgen excess (e.g., PCOS)
• High-dose exogenous androgens
• Nephrotic syndrome

In PCOS, SHBG is often 30 to 50% below normal, which amplifies circulating free testosterone even when total testosterone looks only mildly elevated 14. The Androgen Excess and PCOS Society recommends measuring free testosterone (or calculating it from total T and SHBG) rather than relying on total testosterone alone for PCOS diagnosis 14.

Free Testosterone in PCOS: A Diagnostic Anchor

PCOS affects approximately 6 to 12% of reproductive-age women in the United States, according to CDC estimates 15. Biochemical hyperandrogenism, most reliably captured by elevated free testosterone, is one of the three Rotterdam criteria. A patient can meet diagnostic thresholds for free testosterone elevation while total testosterone stays below the upper limit of normal.

Recommended Cutoffs

The Androgen Excess and PCOS Society's 2009 position statement identifies free testosterone above 3.4 to 3.8 pg/mL (by equilibrium dialysis or calculated method) as biochemical hyperandrogenism in reproductive-age women 14. Direct immunoassay results should not be used for this threshold comparison because of assay variability.

Calculated vs. Measured Free T in PCOS Workup

A 2007 study by Vermeulen and colleagues (N=431) found that calculated free testosterone using the Vermeulen formula correlated at r=0.98 with equilibrium dialysis results across a wide range of SHBG concentrations 3. The calculated approach is practical for routine PCOS evaluation when dialysis is not readily accessible.

Free Testosterone and Testosterone Replacement Therapy: Dose Titration

For men and women receiving exogenous testosterone, free testosterone guides dose adjustments more precisely than total testosterone because it reflects actual androgen receptor stimulus.

Men on TRT

The Endocrine Society's 2018 guideline recommends checking free testosterone 3 months after any dose change and targeting a mid-normal range 8. Common titration errors occur when clinicians use total testosterone alone: a man with low SHBG (often from obesity or metabolic syndrome) can show a normal total T while his free T is supraphysiologic, increasing erythrocytosis and cardiovascular risk 16.

The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, found that testosterone-replacement therapy in men with hypogonadism and high cardiovascular risk did not significantly increase major adverse cardiovascular events compared with placebo over a mean follow-up of 33 months, with free testosterone maintained in the mid-normal range throughout 17.

Women on Testosterone Therapy

No testosterone product is currently FDA-approved for women, but off-label use is widespread for hypoactive sexual desire disorder (HSDD) and other androgen-deficiency symptoms. The Global Consensus Position Statement on female testosterone therapy (published in the Journal of Clinical Endocrinology and Metabolism, 2019) recommends targeting free testosterone in the upper quartile of the normal premenopausal female range, approximately 2.5 to 3.4 pg/mL 18. The statement explicitly cautions against supraphysiologic free testosterone because long-term cardiovascular and breast-cancer safety data at those levels are absent 18.

Optimal Free Testosterone: What the Evidence Actually Supports

"Optimal" is not a synonym for "highest tolerated." The evidence associates specific free testosterone windows with favorable outcomes in each sex.

Optimal Range for Men

Studies from the European Male Aging Study (EMAS, N=3,369) found that men with free testosterone in the upper-normal range (roughly 10 to 18 pg/mL) reported better sexual function, lean mass, and bone mineral density than those below 7 pg/mL, without an increase in adverse events 19. Above roughly 20 pg/mL, erythrocytosis risk increases and HDL cholesterol may fall 16.

Optimal Range for Women

The 2019 Global Consensus Position Statement defines the target as matching premenopausal female norms. Free testosterone above 3.8 pg/mL in women has been associated with acne, hirsutism, voice deepening, and potentially adverse lipid shifts, so staying within the premenopausal window is the current clinical standard 18.

A practical decision framework for free testosterone interpretation across four clinical scenarios:

| Scenario | Action | |---|---| | Low free T, normal total T, high SHBG | Address SHBG driver first (e.g., switch oral to transdermal estrogen); recheck before prescribing T | | Low free T, low total T, normal SHBG | Work up primary or secondary hypogonadism | | High free T, normal-high total T, low SHBG | Screen for PCOS or exogenous androgen source | | High free T on TRT | Reduce dose or extend interval; check hematocrit and lipids |

Measurement Pitfalls and Pre-Analytical Variables

Getting an accurate free testosterone result requires attention to several practical details that are easy to overlook.

Timing the Draw

For men, morning draws (07:00 to 10:00) are standard 7. For women, recording cycle day on the requisition is non-negotiable. A mid-luteal free testosterone is not comparable to a mid-follicular value from a different cycle.

Assay Selection Matters

The direct analog immunoassay for free testosterone, which many commercial labs report by default, systematically overestimates free testosterone at low concentrations and underestimates it at high concentrations. A 2008 study in Clinical Chemistry (N=212) found that the direct assay agreed with equilibrium dialysis in only 51% of samples when the true free T was below 2 pg/mL 20. When precision matters, order equilibrium dialysis free testosterone or provide SHBG and albumin for a calculated result.

Specimen Handling

Free testosterone is temperature-sensitive. Samples held at room temperature for more than 4 hours before centrifugation show measurable degradation. Serum should be separated and refrigerated promptly.

Free Testosterone Across the Lifespan: A Summary View

Testosterone production follows a predictable arc from birth through late life, with free testosterone mirroring those changes and amplifying them when SHBG shifts in parallel.

Neonatal and Pubertal Phases

In male neonates, a testosterone surge between weeks 1 and 3 drives early genital development. By age 6 months, total and free testosterone fall to childhood baseline. The pubertal surge in boys begins around age 9 to 11 and free testosterone reaches adult male levels by approximately age 17 21. In girls, adrenarche (typically age 7 to 9) produces a modest rise in adrenal androgens, and free testosterone reaches adult female levels by approximately age 16.

The Late-Reproductive and Perimenopausal Window

Women lose roughly 50% of their peak androgen production between ages 20 and 40, mostly due to declining ovarian androstenedione output. This decline precedes menopause and is largely independent of the estrogen drop 22. Free testosterone in perimenopausal women may actually rise transiently in the late perimenopause as SHBG falls along with estradiol, before declining in the postmenopausal years.

Late Life

After age 70 in men, free testosterone below 5 pg/mL is common but not automatically an indication for TRT. The Endocrine Society guideline notes that symptoms (reduced libido, fatigue, loss of lean mass) must accompany biochemical deficiency before treatment is initiated 8.

Ordering and Interpreting Free Testosterone in Clinical Practice

A systematic approach reduces missed diagnoses and unnecessary treatment.

Minimum Panel for Meaningful Interpretation

Order free testosterone alongside total testosterone, SHBG, LH, FSH, albumin, and a complete blood count. Prolactin and thyroid-stimulating hormone (TSH) should accompany the panel when hypogonadism is suspected, because hyperprolactinemia and thyroid dysfunction both alter SHBG and androgen metabolism 8.

Repeat Testing Threshold

A single low free testosterone result is insufficient for a hypogonadism diagnosis in men. The Endocrine Society requires two morning samples on separate days before initiating TRT 8.

Monitoring Frequency on Therapy

Check free testosterone at 3 months post-initiation, then at 6 months, then annually if stable. In women on testosterone therapy, the Global Consensus recommends checks every 6 months because the therapeutic window is narrow and supraphysiologic levels can develop quickly with small dose increases 18.